Previous 10 | Next 10 |
Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria Compelling strategic fit that will expand p ipeline of potential first-in-class therapies targeting rar...
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the fin...
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase...
Retrophin (RTRX) announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy.Topline efficacy data from the 36-week proteinuria endpoint analysis are expected in Q3 2021. "As a result of achi...
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN). The PROTECT Study protocol provides fo...
BofA analyst Scott Puckhaber has initiated coverage on Retrophin ( RTRX +3.9% ) with a Buy rating and $30 (56% upside) price target. More news on: Retrophin, Inc., Healthcare stocks news, Read more ...
The following slide deck was published by Retrophin, Inc. in conjunction with this Read more ...
Retrophin, Inc. (RTRX) Q2 2020 Earnings Conference Call July 30, 2020 16:30 ET Company Participants Chris Cline - Vice President, Investor Relations and Corporate Communications Eric Dube - Chief Executive Officer Noah Rosenberg - Chief Medical Officer Peter Heerma - Chief Comm...
Retrophin (NASDAQ: RTRX ) : Q2 Non-GAAP EPS of -$0.22 beats by $0.14 ; GAAP EPS of -$0.58 misses by $0.03 . More news on: Retrophin, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased eight percent to $48 million in the second quarter Cash & equivalents of $457 m...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on Novem...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58...